To the Editor: Recently, Schaefer et al. 1 reported that whole genome sequencing (WGS) of two Cas9-treated, gene-corrected mice and a wild-type control mouse unveiled 1,397 singlenucleotide variations (SNVs) and 117 small insertions and deletions (indels) present commonly in the two Cas9-treated mice "but absent in the uncorrected control" and from a database of mouse SNVs and indels. There was essentially no sequence homology between the on-target site and these SNVs and indel sites, most of which lacked a protospaceradjacent motif (PAM) sequence, suggesting that these variations were both small guide RNA (sgRNA)-independent and Cas9-independent, respectively. Nevertheless, the authors made
a bold claim that these variations were caused by CRISPR-Cas9 without validating these unexpected off-target effects even at a single SNV or indel site by performing an independent experiment in vitro or in vivo. Another major concern in Schaefer et al. is the absence of analysis of variants that are present in the control mice but absent in the two gene-edited mice.
Target specificities of CRISPR systems have been extensively studied in animals and cell lines. For example, we showed that certain CRISPR-Cas9 nucleases did not induce detectable off-target mutations at sites with just two or three-nucleotide mismatches in human cells, first using T7 endonuclease I assays 2 and then using targeted deep sequencing 3 . We and others also performed WGS to show that Cas9 rarely induced off-target indels in a clonal population of cells [4] [5] [6] [7] or a gene-edited animal 8 . Note that Schaefer et al. did not find any off-target mutations in the two Cas9-treated mice at the top 50 most likely off-target sites with 3-to 4nucleotide mismatches, in line with these previous reports. Given the remarkable specificity of CRISPR-Cas9, it is difficult to believe that Cas9 can cleave sites that differ by > 10 nucleotides from the on-target sequence, as suggested in Schaefer et al.
The authors did not articulate whether the unexpected off-target effects were limited to the particular target site or their method or FVB/NJ zygotes used in their experiments. In silico offtarget predicting algorithms and cell-based, genome-wide off-target profiling methods such as GUIDE-seq 9 and HTGTS 10 cannot identify off-target sites with no sequence homology.
However, Digenome-seq, an in vitro method of capturing in vitro cleavage sites using Cas9digested, cell-free genomic DNA via WGS, does not rely on sequence homology 4 , because DNA double-strand break ends remain intact in vitro and are protected from digestion by endogenous exonucleases in vivo. Note that we did not find any unusual, non-homologous off-target sites in human genomic DNA using Digenome-seq 4 , showing that such sites cannot be cleaved by Cas9 in vitro.
It is also suspicious that they found a 12-fold excess of SNVs over indels. S. pyogenes Cas9 rarely produces SNVs even at on-target sites. After analyzing our targeted deep sequencing data, we found that Cas9 could induce SNVs, when a single base pair (bp) was deleted at a cleavage site and, at the same time, a single bp was inserted, a very rare event that occurred at frequencies of < 1% at on-target sites. Off-target SNVs can be induced much less frequently. In contrast to Cas9-induced mutations, naturally-occurring genetic variations between siblings or strains are strongly biased towards SNVs rather than indels, further casting doubt on "unexpected mutations".
Accordingly, we hypothesized that the two gene-corrected, possibly sibling, mice were genetically distant from the control "co-housed" mouse, although Schaefer et al. indicated that all three mice might belong to the same inbred FVB/NJ strain, and that the SNVs and indels were not caused by CRISPR-Cas9 but inherited from their parents. To test this hypothesis, we used Strelka 11 and Mutect 12 that had been employed by Schaefer et al. to find SNVs which are different between two samples in any pairwise-combination of F03, F05, and FVB. We found the lowest number of sample-specific variants when comparing the two samples F03 and F05 ( Fig. 1a) , while in comparisons including FVB the number of sample-specific variants was considerably higher. Strikingly, this was not only the case for variants present in F03/F05 (and not in FVB), but also for variants present in FVB (and not in F03/F05). To preclude a calling bias caused by the different sequencing depth of F03/F05 and FVB, we used the multi-sample variant caller Platypus 13 to analyze shared and sample-specific variants ( Fig. 1b and 1c ). This analysis confirms that FVB bears a similar number of variants which are not present in F03/F05 as vice versa. Furthermore, most variants not present in FVB are shared between F03 and F05, and are homozygous in both of the samples. It is virtually impossible that any mutagenic process causes such a pattern. Finally we focused on the heterozygous variants in the three mice. Mice from inbred strains are generally not expected to contain substantial numbers of heterozygous variants, whereas mutagenic processes will in the vast majority cause heterozygous mutations. While there are indeed heterozygous variants in F03 and F05 which are sample-specific or shared between those samples, the number of heterozygous variants is higher in FVB. The largest fraction of heterozygous variants is shared between all three mice, proving that these variants are inherited and not individually acquired in the investigated animals. Altogether, these results demonstrate that there is considerable genetic heterogeneity between the three mice, with F03 and F05 being genetically closer to each other than to FVB.
In summary, the CRISPR-Cas9-treated mice do not exhibit more variants that are absent in the uncorrected control than vice versa. Furthermore, the observed variants are extremely unlikely a consequence of a mutagenic process in the investigated animal, but are much better explained by differences in the genetic background between the two gene-edited mice and the control mouse. We conclude that the data presented by Schaefer et al does not provide any evidence for off-target mutagenesis due to CRISPR-Cas9 treatment and see no reason to be doubtful about the previous findings that Cas9 does not cause SNVs and indels at nonhomologous, PAM-free sites. 
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